ClinicalTrials.gg
TerminatedNCT01698944Updated Feb 27, 2017

Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone Deficiency

A Phase 4 interventional study of somatropin in Growth Hormone Disorder and Adult Growth Hormone Deficiency, sponsored by Novo Nordisk A/S. Terminated at 1 site in Greece. Open to participants aged 12 Years to 25 Years. Per ClinicalTrials.gov, last updated 2017-02-27.

Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment

Why this study was terminated
The trial was prematurely terminated due to low recruitment

From the registry’s dates

  • Registered 11 years 4 months after the study started (first participant enrolled May 2001, registered Oct 2012).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
7
Allocation
Non-randomized
Ages
12 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.

Enrollment
58th of 60
7 · median 66
Started
2001
with 1 other
Phase 4
19 of 60
none open now
Registered
44th of 60
by date
Lead sponsor
8 of 60
Novo Nordisk A/S

Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one is the 58th largest by enrollment, is one of 2 that started in 2001, is one of 19 in phase 4, and was the 44th registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 12 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, or all of them as a file.
02

Study summary

This trial is conducted in Europe. The aim of this trial is to investigate the effect of growth hormone on left ventricle morphology and function (systolic and diastolic).

03

Conditions studied

  • Growth Hormone Disorder
  • Adult Growth Hormone Deficiency

Browse trials for

04

Who can participate

Ages eligible
12 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult growth hormone deficiency
  • At least 2 years without growth hormone treatment

Exclusion criteria

Exclusion Criteria:

  • Supine blood pressure above 160 mmHg systolic or above 100 mmHg diastolic
  • Pregnancy
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Somatropin

    Drug: somatropin

Interventions

  • Initial dose 0.5 IU/day and escalated up to maximum dose the first 6 months. Maximum dose 3.0 IU/day for 18 months. Injected subcutaneously (s.c., under the skin) daily

06

What researchers measure

Primary outcomes

  1. Left Ventricular systolic function

  2. Left Ventricular diastolic function

Secondary outcomes

  1. Body composition

  2. Fasting glucose

  3. HbA1c (glycosylated haemoglobin)

  4. Oral glucose tolerance test (OGTT)

07

Study locations

1 site
  • Novo Nordisk Investigational Site
    Athens, GR-11527, Greece
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2001 to primary completion in Nov 2002, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2012
First posted
Oct 3, 2012
StartActual
May 16, 2001
Primary completionActual
Nov 18, 2002
CompletionActual
Nov 18, 2002
Last update
Feb 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01698944
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Oct 3, 2012
Start date
May 16, 2001
Primary completion
Nov 18, 2002
Completion
Nov 18, 2002
Last update
Feb 27, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion